

daewon


Healthy innovation for the world
Daewon Pharm, a total healthcare group



Advanced healthcare company, for better life.

Since 1958

Daewon Pharm
began its journey in Busan Korea.



“Do not turn away those who come in need with nothing”

Founded in 1958, with the belief of helping patients suffering from lack of medicine, Daewon Pharmaceutical has steadfastly walked the path of a dedicated pharmaceutical company, driven by the genuine commitment to people and life.

Beginning with the success of "Pelubi Tab," Korea's 12th independently developed new drug, Daewon Pharm has proven its technological and business capabilities through top-tier research, development, and commercialization of incrementally modified drugs (IMDs). It has since pioneered the pouch-type syrup market with popular products such as Codaewon-S, Codaewon Forte, and the Coldaewon series, offering a wide range of beloved medicines to the public.

Backed by product excellence and dynamic growth, Daewon Pharm has secured its position as a key player in Korea's pharmaceutical and biotech industry. Now, leveraging its accumulated expertise and technology, the company is expanding into various healthcare sectors to realize "total life care." Committed to promoting healthier, higher-quality lives, Daewon Pharmaceutical pledges to remain your most trusted partner.

History

Daewon Pharm, with a 68-year history

Since its foundation in 1958, Daewon Pharm has established itself as a deeply rooted Korean pharmaceutical company committed to safeguarding public health. Built on trust and confidence from our customers, we continue to fulfill our mission as a global healthcare company and a reliable partner in promoting healthier lives for humanity. As we approach our 70th anniversary, we will continue our journey toward a healthier and happier future, looking ahead to our centennial and beyond.



1958~1999

- Jan. 1958 Established Daewon Pharmaceutical Company (Nambumin-dong, Seo-gu, Busan Korea).
- Jun. 1965 Relocated its head office (Sinmunro, Jongno-gu, Seoul Korea).
- Dec. 1970 Won an approval of psychotropic drugs.
- Sep. 1988 Built Hyangnam Plant.
- Sep. 1989 Established Central R&D Center.
- Oct. 1994 Registered to KOSDAQ.
- Dec. 1999 Listed in Korea Exchange (003220.KS).



2000~2019

- Apr. 2007 Won an approval of Pelubi Tab. as the 12th new drug.
- Nov. 2016 Awarded Minister Prize at Korea Technology Awards (Pelubi CR Tab.; Ministry of Trade, Industry and Energy).
- Feb. 2009 Awarded Technology Prize at Korea New Drug Award (Pelubi Tab.; Korea Drug Research Association)
- Feb. 2017 Received IR52 Jang Young-sil Award (Renamezin Cap.)
- Apr. 2009 Completed renovation of Hyangnam Plant at the cGMP level.
- Dec. 2017 Certified as a family friendly company (Ministry of Gender Equality and Family).
- Jun. 2012 Selected as Korea Innovative Pharmaceutical Company (Ministry of Health and Welfare).
- May. 2018 Obtained anti-bribery management system ISO-37001 certification.
- Mar. 2015 Selected as Top 100 Employer (Ministry of Employment and Labor).
- Dec. 2018 Awarded Grand Prize at Korea Pharmaceutical Industry Advertisement Awards for squeeze-to-eat cold remedy 'Coldaewon.'
- Dec. 2015 Awarded Grand Prize at the 24th Best Enterprise Award (Citizens' Coalition for Economic Justice).
- Jun. 2019 Built Jincheon New Plant as the smart factory.
- Feb. 2016 Awarded Technology Prize at Korea New Drug Award (Pelubi CR Tab., Korea Drug Research Association)
- Oct. 2019 Grand Honor Medal for Distinguished Service as a Red Cross Member (Korean Red Cross)
- Jul. 2016 Selected as Top 100 National R&D Excellence (Pelubi CR Tab.; Ministry of Science, ICT and Future Planning)



2020~

- May. 2021 Received Prime Minister Citation for contribution to employment equality from Ministry of Employment and Labor.
- Jan. 2024 Surpassed KRW 500 billion in sales.
- Jun. 2021 Took over Daewon Healthcare (Former Keukdong H-Pharm).
- Feb. 2024 Acquired SD Biotechnologies.
- Apr. 2022 Jangdaewon (health functional food brand) was awarded Main Prize at 'iF Design Award.'
- Jun. 2024 Selected as a Korea Innovative Pharmaceutical Company for five consecutive terms.
- Dec. 2022 Selected as Lighthouse Company of New Market Area by the Ministry of Trade, Industry and Energy.
- Nov. 2024 Received a commendation from the Minister of Trade, Industry and Energy for establishing a cooperation system with Meister High School.
- Jan. 2023 Hyangnam and Jincheon Plant, obtained the safety and environment ISO 14001 45001 certifications.
- Mar. 2025 Expanded the logistics building of Jincheon Plant.
- Feb. 2023 Won Technology Prize at Korea New Drug Award (Codaewon S; Korea Drug Research Association).

Intro

Company Overview

68+

With 68 years of history,
a total healthcare company

598.2 KRW
billion

598.2 billion KRW in sales in 2024
13.5% growth compared to the previous year

17,872 cell

The largest pharmaceutical logistics center in Korea

1,332 people

Executives and employees shaping
the future together with Daewon Pharm.

1ST

Ranked 1ST in the syrup and suspension market

1ST

Ranked 1ST in the respiratory and ENT market

We are

Company Vision & Core Values

Daewon Pharm aims to realize true life care by providing safer and more effective treatments through advanced pharmaceutical and biotechnological expertise, while expanding into a diverse range of healthcare sectors to help foster healthier lifestyles.

In the era of 100-year lifespans, Daewon Pharm promises to remain a constant presence in people's lives, supporting them in leading healthy and vibrant lives.

Healthy Innovation for the World




Advancing as a global healthcare company through bold innovation in R&D, quality, and beyond.



Challenge & Innovation

A spirit of challenge that drives change




Passion & Growth

Passion in pursuit of excellence



Customer & Trust

Flawless actions that build trust



Communication & Respect

A mindset that values and respects life

ESG

Sustainability Management

ESG Ratings and Certifications

Sustainvest



Grade A (GOLD)

KCGS (Korea Institute of Corporate Governance and Sustainability)



Overall B+

Environment B+

Social A

Governance B

Sustainability Certifications

Environment (E) Safety (S) Labor (S) Compliance (G)
ISO 14001 ISO 45001 Family-Friendly Business Certification ISO 37001



To advance its sustainable management, Daewon Pharm is implementing ESG management under the vision of "A Sustainable Future with a Healthy Life."

The company has established three key strategic directions: Carbon neutrality, leadership in social responsibility, and transparent management.

E Environment

- ▶ With the ultimate goal of achieving carbon neutrality by 2050, Daewon Pharm transparently discloses its environmental indicators and continuously manages its environmental performance.
- ▶ Placing eco-friendly management as a top priority, both the Jincheon Plant-Korea's largest liquid formulation facility-and the Hyangnam Plant have obtained ISO 14001 Environmental Management System Certification, striving to minimize environmental impact.
- ▶ Constructed a smart factory to maximize energy efficiency and resource conservation.
- ▶ Eco-friendly corporate culture (promoting energy-saving campaigns and reducing carbon emissions through product donation initiatives).
- ▶ Continuously pursuing production process innovation and the adoption of energy-saving technologies.

S Social

- ▶ Prioritizes the safety and well-being of employees by fostering a positive workplace culture through various welfare programs and a robust safety management system.
- ▶ Certified with the Occupational Health and Safety Management System (ISO 45001).
- ▶ Promotes mutual growth with local communities through activities such as donating Cureban Burn Spray to firefighters, contributing Jangdaewon health supplements, kimchi-sharing events, and the Daewon Harmony volunteer program.
- ▶ Operates a rigorous quality control system to consistently provide trusted products to customers.
- ▶ Contributes to public health by developing various IMDs and combination drug formulations.

G Governance

- ▶ strives to build trust with stakeholders through transparent and ethical management.
- ▶ Certified with the Anti-Bribery Management System (ISO 37001).
- ▶ The Board of Directors promotes the company's long-term growth through independent and objective decision-making.
- ▶ Continuously works to enhance the diversity and independence of the Board.
- ▶ Strengthens internal controls and provides regular training to ensure all executives and employees adhere to ethical standards.
- ▶ Established and operates an ESG Committee within the Board of Directors on a regular basis.

Performance

A leading player in Korea's pharmaceutical and biotech industry

Since its establishment in 1958, Daewon Pharm has been dedicated to the development of high-quality prescription drugs for over six decades.

Leveraging its outstanding R&D capabilities, the company successfully developed and commercialized Korea's 12th new drug, Pelubi, along with a wide range of stick-type pouch syrups, demonstrating its strong business capabilities. Backed by a powerful sales network, Daewon Pharm has focused its marketing efforts to launch numerous blockbuster products across various disease categories, solidifying its position as a leading player in Korea's pharmaceutical and biotech industry.

Outstanding product quality

ENT, respiratory market

65.5% share in ENT(otolaryngology) prescriptions (2024)

No.1 in outpatient respiratory prescriptions (2024; ATC R)

*Based on data from UBIST and the Health Insurance Review & Assessment Service (HIRA)

No.1

Cutting-edge facilities and production systems

Syrup and suspension market

26.0% M/S (2024)

Holds the largest and most advanced production capacity in Korea

No.1

Domestic and international technology patents

Patents filed: 124
Patents registered: 52

14 blockbuster products

Products across various disease categories

14 products with annual sales exceeding 10 billion KRW each

Powerful sales network

Primary healthcare market

Holds 35.3% of clinics as continuously prescribing clients (2024)

Ranked 3rd in the clinic outpatient market

No.3

Sales

Daewon Pharm has maintained steady annual sales growth, recording 598.2 billion KRW in sales in 2024 (YoY +13.5%).

↗ 2014 - 2024 CAGR

12.6%

10-year compound annual growth rate: 12.6%


📊 Total sales in 2024

598.2 KRW billion

📊 Operating profit in 2024

28.2 KRW billion

Based on consolidated figures from DART electronic disclosures and business reports




Export

Exports to 45 countries worldwide

Daewon Pharm began its first export to Vietnam in 1994, leveraging its high-quality domestic manufacturing facilities and strict quality control systems.

Today, the company is exporting pharmaceuticals and health supplements to approximately 45 countries, including major Asian markets such as Japan, as well as regions in Latin America, the Middle East, the CIS, and Africa.



- 1996 Awarded the Million Dollar Export Tower.
- 2000 Selected as an outstanding export enterprise.
- 2004 Awarded the Three Million Dollar Export Tower.
- 2004 Established sales corporation in Vietnam.
- 2007 Awarded the Five Million Dollar Export Tower.
- 2010 Awarded the Ten Million Dollar Export Tower.
- 2013 Achieved USD 20 million in exports.
- 2020 Exported anesthetics for COVID-19 treatment.
- 2022 Mongolia's "Coldwon" advertisement on air
*Coldwon = 'Coldeawon' export product name)




Compliance

Ethical and Compliance Management

In response to the growing demands for ethical and compliance-based management in an ever-changing era, Daewon Pharm began its journey in 2007 by establishing and implementing its Code of Ethics during the early stages of voluntary compliance in the pharmaceutical industry. The company has achieved several milestones, including the CP (Compliance Program) rating assessment in 2016 and the acquisition of ISO 37001, the international standard for anti-bribery management systems, in 2018. Daewon continues its efforts to go beyond these achievements by embedding a culture of compliance and anti-corruption throughout the organization.

Key initiatives for ethical management and anti-corruption

- 01 Established an anti-corruption policy applicable to all executives and employees (clearly prohibiting corrupt practices involving any stakeholders).
- 02 Conducted specialized training and written evaluations on fair trade and anti-bribery management systems by department and job level.
- 03 Developed, continuously improved, and monitored fair trade compliance regulations for sales and marketing activities.
- 04 Strengthened human resource capabilities for compliance and anti-corruption (through certifications such as ISO 37001 auditor and Certified Compliance Officer).



Research & Development

Overview

Since establishing its Central Research Institute in 1989, Daewon Pharm has been developing a wide range of prescription drugs across various disease categories, including cardiovascular, respiratory, gastrointestinal, endocrine systems, as well as antibiotics and chemotherapeutic agents. As a company equipped with new drug development capabilities, Daewon Pharm. Co., Ltd. continues to pursue innovative new drug research, evolving into a globally recognized R&D-driven pharmaceutical company.

R&D expenditure in 2024


46.5 KRW billion


Ratio of R&D personnel to total workforce


Master's and Ph.D. holders: 71.1% (108 individuals in total)

11.4%

As of Q4 2024 (separate basis), according to the business report and IR materials

 R&D ratio [as a percentage of sales]




 R&D personnel status



R&D Vision

Focusing on securing future growth engines through differentiated new drugs

The core of Daewon Pharm's future growth lies in new drug research and development. To this end, the company is dedicating its full organizational capabilities to R&D. While securing short-term growth through the development of IMDs, the company is also laying the foundation for future growth by discovering new compounds, developing natural product-based new drugs, and pursuing differentiated formulations. In the mid-to-long term, the company aims to become a top-tier pharmaceutical leader through new drug development based on novel compound synthesis and the development of biopharmaceuticals.



Pipelines

Focused development of new drugs and IMDs

Daewon Pharm is developing multiple new drugs with the goal of creating best-in-class treatments. Currently, the company is conducting research on five innovative new drug projects. Its IMD strategy focuses on chronic diseases, with a primary emphasis on metabolic disorders and cardiovascular conditions, aiming to develop highly competitive products in these areas. Active research is also underway for IMDs targeting the endocrine, circulatory, and respiratory systems.

Overview of new drug pipeline

Project Code	Disease Category	Features	Development Phase				
			Exploratory Study	Preclinical Study	Clinical Study	Authorization	Launch
DW-4902	Uterine fibroids	-	████████████████████				
DW-4222	Obesity	Oral formulation	████████████████████				
DW-4421	Gastroesophageal reflux disease	-	████████████████████				

Overview of new technology pipeline

Project Code	Disease Category	Features	Development Phase				
			Exploratory Study	Preclinical Study	Clinical Study	Authorization	Launch
DW-1022	Microneedle patch	Dosage form modification	████████████████████				
DW-1023	Drug-delivering contact lens	Extended duration of action	████████████████████				
DW-1121	Inhaler	Dosage form modification	████████████████				

Overview of IMD pipeline

Project Code	Disease Category	Features	Development Phase				
			Exploratory Study	Preclinical Study	Clinical Study	Authorization	Launch
DW-1805	Endocrine disorders	Dosage form modification	████████████████████				
DW-1125	Hyperlipidemia	Miscellaneous	████████████████████				
DW-1122	Endocrine disorders	Dosage form modification	████████████████████				
DW-1222	Endocrine disorders	Dosage form modification	████████████████████				
DW-5121	Respiratory disorders	Combination formulation	████████████████████				
DW-1807	Respiratory disorders	Combination formulation	████████████████████				
DW-1026	Endocrine disorders	Combination formulation	████████████████████				
DW-5421	Hyperlipidemia	Combination formulation	████████████████████				
DW-1021	Pain reliever	Miscellaneous	████████████████				

Technology

Core technologies and patents

Core technologies

Category	Core Technology	Product	Efficacy
Controlled release (SR)	Controlled Release Hydrophilic matrix system Multi-Layer tableting Floating Release	Pelubi SR Tab. Wontran ER Tab. TG Fenon Tab. Otilen F Tab.	Anti-inflammatory analgesic Treatment of acute and chronic pain Treatment of hypertriglyceridemia Treatment of acute and chronic gastritis
Absorption enhancement (Sol, BA improvement)	Micro emulsion Solid dispersion Nanoparticulation	Freepol-MCT Inj. Twyncombi Tab. Daewon Megetrol ES Suspension	Induction of general anesthesia Treatment of hypertension Treatment of loss of appetite
Miscellaneous	Fast Dissolving Technology Taste Masking Technology	Clasin Dry Syrup Elstein	Treatment of bronchial infections Mucolytic and expectorant action

Patents

Category	Patent Applications	Granted Patents
Domestic Patents	75	39
International Patents	49	13

Manufacture & Subsidiary Company

Manufacture

ISO Certifications

Hyangnam Plant

- Occupational Health and Safety Management System – ISO 45001
- Environmental Management System – ISO 14001

Jincheon Plant

- Occupational Health and Safety Management System – ISO 45001
- Environmental Management System – ISO 14001



Hyangnam Plant

Completed in 1988, the Hyangnam Plant is equipped with advanced pharmaceutical manufacturing facilities and a robust quality control system. It produces a wide range of products including solid oral preparations, injectables, and sex hormone medications. In 2009, the plant underwent a full-scale renovation to meet cGMP standards, incorporating state-of-the-art IT systems to ensure high-quality pharmaceutical production. Based upon these systems, the plant has secured strong competitiveness in manufacturing excellence and conducts in-process inspections and rigorous quality control using advanced analytical equipment.

► Core Production Operation Systems

Quality Management System (QMS)

Raw Material Weighing System (RWS)

Laboratory Information Management System (LIMS)

Building Management System (BMS)

Video materials

Scan the QR code below to explore the production processes of each plant.



Hyangnam Plant



Jincheon Plant



Jincheon Plant

Completed in 2019, the Jincheon Plant is a smart factory equipped with cutting-edge facilities and production systems that meet cGMP standards. To ensure high-quality pharmaceutical manufacturing, the plant has “fully automated” the entire process—from formulation and filling to packaging, transfer, and logistics—thereby maximizing production efficiency.

As the production hub for Daewon Pharm. Co., Ltd.’s liquid syrup products such as Codaewon-S, Codaewon Forte, and Coldaewon, the Jincheon Plant houses the largest liquid formulation production facility in Korea. In 2025, the logistics center underwent a major upgrade, expanding its storage capacity from 6,500 to 17,872 cells. This expansion enhanced operational efficiency, contributed to environmental sustainability, and maximized the effectiveness of the logistics system.

► Core Production Operation Systems

Quality Management System (QMS)

Laboratory Information Management System (LIMS)

Building Management System (BMS)

Transfer Delivery System (TDS)

Conveyor System (CVS)

Automated Packaging Robot System

Warehouse Management System (WMS)

CMO

Daewon Pharm CMO capabilities, offering comprehensive total services from product development to finished pharmaceutical products, represent another key competitiveness of the company. Based upon its advanced GMP-grade facilities, the company has been recognized for supplying a wide range of pharmaceutical formulations to leading pharmaceutical companies.

↗ 2014 - 2024 CAGR

9.0%

10-year compound annual growth rate: 9.0%


📊 Total sales in 2024

71.0

KRW billion

Based on internal accounting system data

[Unit: KRW 100 million]



Subsidiary

ISO Certifications

daewon Healthcare

- Quality Management System – ISO 9001
- Environmental Management System – ISO 14001

SD BIOTECHNOLOGIES

- Food Safety Management System – ISO 22000
- KMF Halal Certification



daewon Healthcare

Since its establishment in 1996, Daewon Healthcare has been dedicated to ensuring the highest standards of quality and safety as a specialized manufacturer of health functional foods. As a GMP-certified company, it continues to strengthen its technological capabilities and competitiveness through ongoing research and development. The company has also made notable progress in both human and animal health supplement sectors, positioning itself to grow into a comprehensive healthcare provider. With a vision to become a trusted partner for a healthier future, Daewon Healthcare is committed to respecting life and striving toward a better tomorrow.



SD BIOTECHNOLOGIES

Established in 2008, SD Biotechnologies is a cosmetics and food distribution company that develops high-quality products through innovative ideas and biotechnology-based R&D capabilities.

The company owns a diverse portfolio of brands, including the high-performance derma skincare line "SNP," the youth-focused skincare brand "SNP prep," the men's care brand "M'SOLIC," and the food brand "Ogam siktak."

Pursuing a balanced and healthy life that embraces both inner and outer well-being, SD Biotechnologies is committed to making the world more beautiful and radiant.

Summary

Different Point of View

01



Rapid growth in OTC and new businesses

- Consumer healthcare division surpassed KRW 40 billion in annual sales
- Expanded product lineup of the Coldaewon series
- Coldaewon Kids ranked No.1 in the children's cold medicine market

02



14 Blockbuster products

- 14 products with annual sales exceeding 10 billion KRW
- Balanced sales distribution across multiple disease categories


03



Korea's largest liquid formulation production base

- Fully automated processes for maximum production efficiency
- Korea's largest pharmaceutical logistics center through advanced logistics optimization

04



Robust nationwide sales network

- Nationwide sales hubs driving business synergy
- Ranked No.1 in ENT and respiratory markets, No.3 in clinics
- Rapid growth and top-tier performance in semi- and general hospitals's

05



Differentiated R&D capabilities

- Leading commercialization record of IMDs in Korea
- Development of differentiated new products

06



Top-tier domestic CMO services

- Sustained high performance among top-tier Korean pharmaceutical companies
- Consistent double-digit growth trajectory

Main Product & Brand

Blockbuster

A total of 14 blockbuster products

Daewon Pharm holds multiple blockbuster products, each generating over 10 billion KRW in annual sales.

Starting with respiratory treatments, the company demonstrates strong and balanced performance across a wide range of disease categories, including antipyretics, analgesics, anti-inflammatory agents, renal, gastrointestinal, endocrine, cardiovascular, and antibiotics.

01

Respiratory

Codaewon S Syrup

코대원에스시럽



02

Respiratory

Codaewon Forte-Syrup

코대원포르테시럽



03

Respiratory

Pelubi Tab.

펠루비정



04

Respiratory

Clasin Tab.

클래신정



05

Musculoskeletal

Pelubi SR Tab.

펠루비서방정



06

Musculoskeletal

Shinbaro Tab.

신바로정



07

Musculoskeletal

Terosa cartridge Inj.

테로사카트리지주



08

Gastrointestinal

Eswonamp Tab.

에스원앰프정



09

Renal

Renamezin Cap.

레나메진캡슐



10

Metabolic disorders

TG Fenon Tab.

티지페논정



11

Metabolic disorders

Tavalozet Tab.

타바로젯정



12

Nervous system

Alfocholine

알포콜린



13

Respiratory

Coldaewon Syrup

콜대원시럽



14

Respiratory

Coldaewon Kids-Syrup

콜대원키즈시럽



MUSCULOSK-ELETAL DISORDERS

Our musculoskeletal product portfolio includes Pelubi SR Tab., which can be prescribed for both acute and chronic pain; Shinbaro, an osteoarthritis treatment suitable for co-administration with NSAIDs; Terrosa Cartridge Inj., indicated for osteoporotic fractures; and knee osteoarthritis treatments such as Artifull and Bonisen Inj.

01

Pelubi SR Tab.

Korea's No.1 prescribed NSAID for 7 consecutive years



Pelubi SR Tab., developed using our patented controlled-release (CR) technology, is an NSAID that provides 24-hour sustained effects with just two daily doses.

The drug maintains a consistent plasma concentration while minimizing gastrointestinal side effects, with only 3–6% of the drug released in the GI tract.

Clinical studies have demonstrated its superior safety profile compared to Aceclofenac.

Originally approved for chronic pain indications such as osteoarthritis, rheumatoid arthritis, and lower back pain, Pelubi SR Tab. received approval for acute pain in 2022, making it a comprehensive solution for all types of pain.

Pelubi SR Tab. has solidified its No.1 position in prescriptions in Korea for seven consecutive years.

* UBIST Analytics, M1-M3 Market, 7-year prescription volume (2018–2024)

MUSCULOSKELETAL DISORDERS

Our musculoskeletal product portfolio includes Pelubi SR Tab., which can be prescribed for both acute and chronic pain; Shinbaro, an osteoarthritis treatment suitable for co-administration with NSAIDs; Terrosa Cartridge Inj., indicated for osteoporotic fractures; and knee osteoarthritis treatments such as Artifull and Bonisen Inj.

02

Shinbaro Tab.

Sustainable treatment for osteoarthritis



Shinbaro Tab. is a SYSADOA (Symptomatic Slow-Acting Drug for Osteoarthritis) that supports the therapeutic effects of NSAIDs, making it suitable for long-term treatment of osteoarthritis. Launched in 2011 as Korea's fourth approved natural product-based new drug, Shinbaro not only offers anti-inflammatory and analgesic effects but also provides cartilage protection, contributing to sustained disease treatment with a strong safety profile. In November 2018, Daewon Pharm began marketing the product through a co-promotion agreement with GC Biopharma, and due to its exceptional market growth rate* compared to competitors, the product was fully transitioned to Daewon Pharm's proprietary lineup in January 2025.

* UBIST Analytics. M5X Market. 2022-2024년 3개년 연평균 성장률 기준

03

Terrosa Cartridge Inj.

For osteoporotic fractures, the bone-forming agent Terrosa



Terrosa is the first teriparatide biosimilar approved in Korea, developed for the treatment of osteoporosis in postmenopausal women and men and women at high risk of fractures. As a self-injectable bone-forming agent, it is administered once daily for up to 24 months in patients at very high risk of osteoporotic fractures. It promotes rapid new bone formation and improves bone quality, accelerating fracture healing and functional recovery. Clinical studies have demonstrated significant improvements in bone mineral density (BMD) and bone formation markers (P1NP); no cases of immunogenicity have been reported, which confirms its strong safety profile. Terrosa continues to show steady market growth* by offering equivalent efficacy and safety to the original drug, along with a clear economic advantage.

* IMS Analytics, Teriparatide Market, 3-year average growth rate (2021-2023)

RESPIRATORY DISORDERS

Daewon Pharm supported by a high market share, maintains strong brand recognition and continues to solidify its leadership in the domestic respiratory infection treatment market through a broad portfolio of products such as Pelubi Tab., Codaewon-S, Codaewon Forte, Symbicort, and Pulmicort.

04

Codaewon-S Syrup

An antitussive and expectorant with proven efficacy, demonstrated through a superiority clinical trial conducted in Korean patients.



Codaewon-S Syrup is a five-ingredient combination antitussive and expectorant containing dihydrocodeine, chlorpheniramine, methylephedrine, ammonium chloride, and Pelargonium, designed to effectively relieve a wide range of respiratory symptoms. Its efficacy was demonstrated through a phase 3 clinical trial conducted in Korean patients, where it showed superiority over both Codaewon Forte Syrup and Pelargonium syrup. In a second clinical study conducted to expand its indications for upper respiratory tract infections, it also showed statistically significant improvements compared to ivy leaf/goldthread extract and placebo. With its proven efficacy and safety through clinical trials, the product has achieved remarkable market success, surpassing 30 billion KRW in sales in 2022, 50 billion KRW in 2023, and 60 billion KRW in 2024—firmly securing its position as the No.1 product in Korea's antitussive and expectorant market. In recognition of its innovation, excellence, and market potential, Codaewon-S Syrup was awarded the 2023 Korea New Drug Development Technology Award.

05

Codaewon Forte Syrup

The first dihydrocodeine combination in Korea formulated in a pouch-type dosage form.



코대원 푸르테 시럽
Codaewon-Forte

Codaewon Forte Syrup is a dihydrocodeine combination syrup, launched in 2014 as the first pouch-type formulation of its kind in Korea. With four key active ingredients providing antitussive, expectorant, antihistamine, and bronchodilatory effects, the product offers fast and powerful symptom relief. Despite being a syrup, it was developed as a sugar-free formulation, significantly enhancing patient convenience and compliance. Owing to these differentiating features, the product recorded 10 billion KRW in sales within two years of launch and surpassed 20 billion KRW by its fifth year, becoming one of Daewon Pharm's flagship products and playing a key role in the company's remarkable growth in the respiratory treatment market.

RESPIRATORY DISORDERS

Daewon Pharm supported by a high market share, maintains strong brand recognition and continues to solidify its leadership in the domestic respiratory infection treatment market through a broad portfolio of products such as Pelubi Tab., Codaewon-S, Codaewon Forte, Symbicort, and Pulmicort.

06

Pelubi Tab.

Korea's 12th approved new drug, an evolving blockbuster with expanding indications



Pelubi Tab. is a pelubiprofen-based NSAID developed entirely in-house by Daewon Pharm from active ingredients to finished product. It was approved by the Ministry of Food and Drug Safety as Korea's 12th domestically developed new drug.

Compared to conventional NSAIDs, Pelubi Tab. offers a rapid onset of action with a T-max of just 30 minutes, delivering fast and effective antipyretic, analgesic, and anti-inflammatory effects with fewer gastrointestinal side effects.

Its small 7-mm tablet size contributes to enhancing patient compliance, and due to strong interest from prescribers, it has maintained the No.1 position in prescription volume in Korea's antipyretic, analgesic, and anti-inflammatory market since 2018.

METABOLIC DISORDERS

Our metabolic disorder portfolio includes treatments for hypertension, dyslipidemia, diabetes, and kidney-related conditions.

Key products include TG Fenon Tab., the smallest triglyceride-lowering agent on the market that can be taken regardless of meals; Tavalozet Tab., a fixed-dose combination of pitavastatin and ezetimibe that helps reduce high LDL-C levels while lowering the risk of new-onset diabetes (NODM); Dapasita -M Tab., a triple combination of SGLT-2 inhibitor, DPP-4 inhibitor, and metformin designed to improve treatment accessibility; and Renamezin Cap., a capsule-type delayed dialysis agent that enhances patient compliance.

07

TG Fenon Tab.

The world's first tablet formulation of fenofibrate choline also the smallest tablet among triglyceride-lowering agents



TG Fenon Tab. is a triglyceride-lowering agent developed by Daewon Pharm. as the first tablet formulation of fenofibrate choline.

By conjugating fenofibrate with choline, the drug achieves improved solubility, and through controlled-release technology targeting the small intestine, it enhances absorption within the body.

Unlike conventional formulations, TG Fenon Tab. can be taken regardless of meals. Its significantly smaller tablet—half the size of existing products—greatly improves dosing convenience.

08

Tavalozet Tab.

Fixed-dose combination of pitavastatin and ezetimibe
Low risk of new-onset diabetes with pitavastatin
Enhanced LDL-C lowering with ezetimibe



Tavalozet Tab. is a treatment for primary hypercholesterolemia, developed as a fixed-dose combination of pitavastatin and ezetimibe by Daewon Pharm. Co., Ltd. By combining pitavastatin—which is known for its low risk of new-onset diabetes—with ezetimibe, the product delivers enhanced LDL-C reduction. It offers an effective therapeutic option for managing LDL-C levels and hypercholesterolemia, especially in patients with metabolic disorders or diabetes.

GASTROINTE-STINAL DISORDERS

Our gastrointestinal portfolio, which includes leading products such as Eswonamp Tab. and Otillen Tab. with annual sales exceeding 10 billion KRW, also features Escorten—the world’s first low-dose PPI developed specifically for gastritis—and Fotagel Suspension, the top enteric adsorbent antidiarrheal in the domestic market by market share.

09

Eswonamp Tab.

The first generic of its kind with improved dosing convenience through reduced tablet size



Eswonamp Tab., containing esomeprazole, was launched in 2014 as the first generic formulation of its kind. Among proton pump inhibitors (PPIs), it provides one of the most potent acid suppression effects and demonstrates excellent efficacy in the treatment and prevention of NSAID-induced peptic ulcers.

Through our proprietary formulation technology, Eswonamp Tab. was developed as the smallest tablet among esomeprazole magnesium trihydrate products, significantly enhancing patient convenience compared to existing alternatives. Thanks to these differentiating features, the product received a strong market response and surpassed 20 billion KRW in sales in 2020, making it one of Daewon Pharm’s top 10 blockbuster products.

10

Escorten Tab.

The world’s first low-dose PPI developed specifically for gastritis treatment



Escorten is the first proton pump inhibitor (PPI) developed specifically for gastritis, marking a new era in gastritis treatment in Korea. Developed through our proprietary formulation technology in 2019, it underwent a Phase 3 clinical trial across 27 general hospitals nationwide in 2020 and was launched in 2021.

Escorten offers excellent acid suppression and outstanding efficacy in relieving gastritis symptoms. It is also the only esomeprazole tablet available in bottle packaging with a compact 5.2 mm tablet size, significantly improving patient convenience. Owing to these differentiating features, Escorten ranked third in prescription volume within the PPI market just two years after launch and is expected to become a promising treatment option for patients with upper gastrointestinal symptoms.

RENAL DISORDERS

The prevalence of chronic kidney disease is steadily increasing in Korea, and it ranks among the highest in terms of medical expenses for a single disease.

We renal treatment portfolio includes key products such as Renamezin, Lowpota, Tolvis, Semerwon, and Repatzin.

11

Renamezin Capsule

Korea's first capsule-type formulation for delaying dialysis



Renamezin, a spherical carbon adsorbent developed by Daewon Pharm over eight years of R&D, is designed to delay the need for dialysis in patients with chronic renal failure and is the first product of its kind to be successfully localized in Korea.

In 2017, Renamezin was recognized for its technological excellence, originality, and innovation with the prestigious IR52 Jang Young-Shil Award, Korea's top industrial technology honor.

Conventional granular formulations often leave residue in the mouth, causing discomfort and reducing patient convenience, while also making accurate dosing difficult.

Renamezin, in capsule form, significantly improves patient convenience while enhancing the adsorption of uremic toxins, thereby contributing to delaying dialysis.

OTC Over-the-Counter PRODUCTS

In addition to Coldaewon, a symptom specific cold remedy, Daewon Pharm. supplies a variety of products across multiple categories—including the vein circulation enhancer “Newbein,” the comprehensive multivitamin “Alldayone,” and the specialized wound care bandage “Cureban”—and is committed to continuously expanding its product lineup to offer consumers an even wider range of solutions.

12

Coldaewon

Launched in 2015, Coldaewon rapidly grew to become Korea’s No.1 cold medicine. A new trend in cold remedies = Easy-to-use, symptom-specific squeeze-type cold medicine

Coldaewon is a squeeze-type cold remedy that can be taken conveniently anytime, anywhere, without water. As the pioneer of stick-type pouch cold medicines, it sparked a strong trend in the market. The single-dose packaging eliminates concerns about product degradation, offers excellent portability, and features a smart-cut design for easy opening. Following the launch of formulations for general cold symptoms (Cold), coughs (Cough), and nasal congestion (Nose), Coldaewon Night, a nighttime cold medicine, was released in 2024, allowing users to choose the right product by color based on symptoms.

Following the adult formulation, the Coldaewon Kids series was developed as a squeeze-type cold medicine for children under 12, allowing easy administration without the need for measuring. The lineup includes three types of cold medicine and two fever reducers (acetaminophen and ibuprofen), making it easy to select based on symptoms. Coldaewon by Daewon Pharm is Korea's No.1 cold remedy brand, trusted by families nationwide as a “must-have household medicine.”



2024 Coldaewon print advertisement



HEALTH FUNCTIONAL FOODS

Daewon Pharm entered the health functional food market in 2015 with the launch of its brand, "Probiotics Jangdaewon." Since then, the company has steadily expanded its product lineup and built strong brand recognition. In 2024, under the slogan "Health Specs for Everyone," Daewon launched the brand "Daewon Health Lab" and began developing individually approved functional ingredients, offering differentiated products in the health functional food market.

13

Daewon Health Lab

A comprehensive health functional food brand helping everyone across the nation build their own "health specs."

"Daewon Health Lab" was launched with a mission to help every Korean enhance their personal "health specs" through trusted, high-quality products. From professional R&D to process, production management, and distribution, Daewon Health Lab takes full responsibility to ensure customer trust and satisfaction. Through continuous R&D, expanding the health spectrum for all—without leaving anyone behind—is the core value of Daewon Health Lab.

From infants and teenagers to adults and seniors, only safe, carefully selected ingredients are used to create the best possible products. Covering digestive health, bone health, blood circulation, liver health, eye health, skin health, and even weight management, Daewon Health Lab offers a wide range of essential products at reasonable prices for comprehensive wellness.



Thank you



daewon Pharm.Co.,Ltd.